Enliven Therapeutics Stock Market Value
| ELVN Stock | 20.74 0.45 2.22% |
| Symbol | Enliven |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Enliven Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Enliven Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Enliven Therapeutics.
| 12/16/2024 |
| 03/16/2025 |
If you would invest 0.00 in Enliven Therapeutics on December 16, 2024 and sell it all today you would earn a total of 0.00 from holding Enliven Therapeutics or generate 0.0% return on investment in Enliven Therapeutics over 90 days. Enliven Therapeutics is related to or competes with Pmv Pharmaceuticals, Cullinan Oncology, Immuneering Corp, Aerovate Therapeutics, MoonLake Immunotherapeuti, Structure Therapeutics, and Compass Therapeutics. More
Enliven Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Enliven Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Enliven Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 16.56 | |||
| Value At Risk | (5.81) | |||
| Potential Upside | 4.27 |
Enliven Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Enliven Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Enliven Therapeutics' standard deviation. In reality, there are many statistical measures that can use Enliven Therapeutics historical prices to predict the future Enliven Therapeutics' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.21) | |||
| Total Risk Alpha | 0.2578 | |||
| Treynor Ratio | 0.3703 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Enliven Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Enliven Therapeutics Backtested Returns
Enliven Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0456, which denotes the company had a -0.0456 % return per unit of risk over the last 3 months. Enliven Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Enliven Therapeutics' Variance of 11.32, mean deviation of 2.43, and Standard Deviation of 3.36 to check the risk estimate we provide. The firm shows a Beta (market volatility) of -0.44, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Enliven Therapeutics are expected to decrease at a much lower rate. During the bear market, Enliven Therapeutics is likely to outperform the market. At this point, Enliven Therapeutics has a negative expected return of -0.15%. Please make sure to confirm Enliven Therapeutics' value at risk, as well as the relationship between the daily balance of power and price action indicator , to decide if Enliven Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.62 |
Good predictability
Enliven Therapeutics has good predictability. Overlapping area represents the amount of predictability between Enliven Therapeutics time series from 16th of December 2024 to 30th of January 2025 and 30th of January 2025 to 16th of March 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Enliven Therapeutics price movement. The serial correlation of 0.62 indicates that roughly 62.0% of current Enliven Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.62 | |
| Spearman Rank Test | 0.57 | |
| Residual Average | 0.0 | |
| Price Variance | 0.6 |
Enliven Therapeutics lagged returns against current returns
Autocorrelation, which is Enliven Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Enliven Therapeutics' stock expected returns. We can calculate the autocorrelation of Enliven Therapeutics returns to help us make a trade decision. For example, suppose you find that Enliven Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Enliven Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Enliven Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Enliven Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Enliven Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Enliven Therapeutics Lagged Returns
When evaluating Enliven Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Enliven Therapeutics stock have on its future price. Enliven Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Enliven Therapeutics autocorrelation shows the relationship between Enliven Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Enliven Therapeutics.
Regressed Prices |
| Timeline |
When determining whether Enliven Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enliven Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enliven Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enliven Therapeutics Stock:
Check out Enliven Therapeutics Correlation, Enliven Therapeutics Volatility and Enliven Therapeutics Alpha and Beta module to complement your research on Enliven Therapeutics. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Enliven Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.